268 results on '"Greenberger, Lee"'
Search Results
52. Multidrug Resistance in the Mouse Macrophage-Like Cell Line J774.2
53. Resistance To Taxanes
54. Downregulation of HER3 by a Novel Antisense Oligonucleotide, EZN-3920, Improves the Antitumor Activity of EGFR and HER2 Tyrosine Kinase Inhibitors in Animal Models
55. Abstract 2456: Discovery of orally active 4-amino-6-arylaminopyrimidine-5-carbaldehyde oximes with dual EGFR and HER2 inhibitory activity.
56. A novel 5-[1,3,4-oxadiazol-2-yl]-N-aryl-4,6-pyrimidine diamine having dual EGFR/HER2 kinase activity: Design, synthesis, and biological activity
57. Discovery of novel 4-amino-6-arylaminopyrimidine-5-carbaldehyde oximes as dual inhibitors of EGFR and ErbB-2 protein tyrosine kinases
58. EZN-2208 (PEG-SN38) Overcomes ABCG2-Mediated Topotecan Resistance in BRCA1-Deficient Mouse Mammary Tumors
59. Abstract 5647: Marked sensitivity to mRNA targeting by LNA antisense in tumor cells without a delivery system: Lessons learned and potential translation to the clinic
60. Reduced Expression of the Androgen Receptor by Third Generation of Antisense Shows Antitumor Activity in Models of Prostate Cancer
61. Abstract A74: Targeting the β-catenin oncogene in multiple myeloma disease using locked nucleic acid technology.
62. Abstract A147: EZN-3920, a HER3 antagonist, enhances the antitumor effect of gefitinib and lapatinib in xenograft models.
63. Drug Conjugates with Poly(Ethylene Glycol)
64. ErbB3 Ablation Impairs PI3K/Akt-Dependent Mammary Tumorigenesis
65. Abstract 5394: Dual inhibition of the androgen receptor by ligand blockade and antisense-mediated downregulation is associated with synergistic antitumor activity model of prostate cancer
66. Abstract 232: Targeting HER3 mRNA by a locked nucleic antisense molecule enhances the antitumor activity of gefitinib in vivo
67. Abstract SY31-02: Locked nucleic acid (LNA)-modified antisense oligonucleotides as anticancer agents: Using high-affinity antisense molecules in the laboratory and in the clinic
68. Tumor Regression and Curability of Preclinical Neuroblastoma Models by PEGylated SN38 (EZN-2208), a Novel Topoisomerase I Inhibitor
69. Abstract 601: In vitro and in vivo inhibition of β-catenin by two novel β-catenin RNA antagonists, EZN-3889 and 3892
70. Abstract 2645: Customized PEG linkers improve the pharmaceutical properties of cytotoxic small molecules
71. Abstract 602: Silencing of the androgen receptor (AR) with a novel mRNA antisense oligonucleotide causes antitumor effects in xenograft models of prostate cancer
72. Abstract 600: Targeting the hedgehog pathway by LNA (locked nucleic acid) oligonucleotide-based GLI2 RNA antagonists, EZN-4482 and EZN-4496, in vitro and in vivo
73. Down-Modulation of Survivin Expression and Inhibition of Tumor Growth In Vivo by EZN-3042, A Locked Nucleic Acid Antisense Oligonucleotide
74. Design, synthesis, and evaluation of 3,4-disubstituted pyrazole analogues as anti-tumor CDK inhibitors
75. Abstract C148: LNA (locked nucleic acid)‐based RNA antagonists mediate target mRNA silencing without transfection by simple addition to cell culture media
76. Abstract C141:In vitroandin vivocharacterization of two novel β‐catenin RNA antagonists, EZN‐3889 and 3892
77. Abstract C215: EZN‐2208, a novel pegylated SN‐38 drug conjugate, markedly inhibits tumor growth and metastatic spreading in preclinical models of human neuroblastoma
78. Abstract C146: LNA (locked nucleic acid) oligonucleotide based GLI2 RNA antagonist EZN‐4482 effectively inhibited tumor growth and increased survival of animals with liver metastasis
79. Abstract C144: A locked nucleic acid antisense oligonucleotode against androgen receptor, down‐modulates target mRNA and causes antitumor effects in xenograft models of prostate cancer
80. Synthesis and evaluation of pyrazolo[3,4- b]pyridine CDK1 inhibitors as anti-tumor agents
81. A RNA antagonist of hypoxia-inducible factor-1α, EZN-2968, inhibits tumor cell growth
82. Novel Prodrugs of SN38 Using Multiarm Poly(ethylene glycol) Linkers
83. Novel Delivery of SN38 Markedly Inhibits Tumor Growth in Xenografts, Including a Camptothecin-11–Refractory Model
84. Design, Synthesis, and Evaluation of 3,4-Disubstituted Pyrazole Analogues as Antitumor CDK Inhibitors.
85. Marked Therapeutic Efficacy of a Novel Polyethyleneglycol-SN38 Conjugate, EZN-2208, in Xenograft Models of Non-Hodgkin’s Lymphoma.
86. Cellular and in Vivo Activity of JNJ-28871063, A Nonquinazoline Pan-ErbB Kinase Inhibitor That Crosses the Blood-Brain Barrier and Displays Efficacy against Intracranial Tumors
87. Synthesis and Biological Study of 4‐Aminopyrimidine‐5‐carboxaldehyde Oximes as Antiproliferative VEGFR‐2 Inhibitors.
88. Synthesis and biological study of 4-aminopyrimidine-5-carboxaldehyde oximes as antiproliferative VEGFR-2 inhibitors
89. Recombinant Human Mannose-Binding Lectin (rhMBL) Binds to Human and Mouse Cancer Cells and Elicits Antitumor Activity in a MBL Knockout Mouse Model of Murine Cancer.
90. Role of the ABCG2 drug transporter in the resistance and oral bioavailability of a potent cyclin-dependent kinase/Aurora kinase inhibitor
91. Preclinical Pharmacologic Evaluation of MST-997, an Orally Active Taxane with Superior In vitro and In vivo Efficacy in Paclitaxel- and Docetaxel-Resistant Tumor Models
92. Paclitaxel-resistant cells have a mutation in the paclitaxel-binding region of β-tubulin (Asp26Glu) and less stable microtubules
93. Two Photoaffinity Analogues of the Tripeptide, Hemiasterlin, Exclusively Label α-Tubulin
94. An Anti-MUC1 Antibody−Calicheamicin Conjugate for Treatment of Solid Tumors. Choice of Linker and Overcoming Drug Resistance
95. Tumor Cells Resistant to a Microtubule-Depolymerizing Hemiasterlin Analogue, HTI-286, Have Mutations in α- or β-Tubulin and Increased Microtubule Stability
96. Cells resistant to HTI-286 do not overexpress P-glycoprotein but have reduced drug accumulation and a point mutation in α-tubulin
97. Synthesis and Biological Activity of Analogues of the Antimicrotubule AgentN,β,β-Trimethyl-l-phenylalanyl-N-[(1S,2E)-3-carboxy-1-isopropylbut-2-enyl]-N1,3-dimethyl-l-valinamide (HTI-286)
98. D-piece modifications of the hemiasterlin analog HTI-286 produce potent tubulin inhibitors
99. Tubulin inhibitors. Synthesis and biological activity of HTI-286 analogs with B-segment heterosubstituents
100. Syntheses and EGFR Kinase Inhibitory Activity of 6-Substituted-4-anilino [1,7] and [1,8] Naphthyridine-3-carbonitriles.
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.